Navigation Links
Takeda Receives New Information on Alogliptin (SYR-322) NDA
Date:3/6/2009

OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA's December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.

Additionally, the FDA does not believe that the amount of existing alogliptin clinical data is sufficient to meet certain statistical requirements in the new guidance. The agency is open to discussions regarding the design of additional CV studies with alogliptin. Alogliptin's Prescription Drug User Fee Act (PDUFA) date - June 26, 2009 - remains unchanged.

In December, 2008 the FDA issued "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes".

In October 2008, Takeda received notification from the FDA that it was unable to complete its review of the alogliptin NDA by the original PDUFA date -- October 27, 2008 -- due to internal resource constraints. The FDA did not raise any issues with the data in the alogliptin NDA at that time. In December 2007, Takeda submitted its NDA for alogliptin to the FDA.

Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.

About DPP-4 Inhibitors

DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase IV (DPP-4), which metabolizes the insulin-increasing hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
2. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
3. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
4. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
5. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
6. Takeda Completes Acquisition of Millennium
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. Takeda Announces New U.S. Leadership
10. Takeda submits new drug application for alogliptin (syr-322) in the US
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... practice! Garden State Urology was formed in 2008, the result of a merger ... the principle that by working cooperatively, they could provide more cost-effective and higher ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, ... Doc”!, Born and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don ... and ice hockey and served as team captain in both sports in his senior year. ...
(Date:8/31/2015)... ... 31, 2015 , ... Dr. Stewart Shofner of Shofner Vision Center ... Month. Only a comprehensive eye examination can diagnose amblyopia. According to the National ... children, affecting approximately 2 to 3 out of every 100 children. , Dr. ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... company announced today that it has officially launched a new website and company ... and brand refresh are more closely aligned with the company’s strategic vision for ...
(Date:8/31/2015)... ... August 31, 2015 , ... Three Bakers Gluten Free Bakery launched the ... more relevant and easy-to-find information on their offering of gluten-free breads and pizzas, living ... an important way for us to share information about our gluten free product offerings, ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... banned all imports of poultry from UK to prevent the spread ... said in statement// as soon as the British ministry informed them ... ,This virus is less dangerous to humans than the H5N1 ... worker in UK. Its incidence of late is on the rise ...
... turn camel milk, a healthier option than cow's milk, into the ... method of milking normally yields some 1.5 litres of milk per ... litres produced by cows. //Yagil, however, says he has developed a ... ,Traditionally seen as riding and pack animals, camels are hugely ...
... a high risk of contracting severe injuries, more specifically sideswipe injuries ... which can be cited in the latest edition of Medical Journal ... driver resting his/her hands on the car window, in a relaxed ... to the protruding limb/elbow. ,In an attempt to identify ...
... the levels of a hormone found in the stomach ... activity in overweight and obese people. // ,The ... International Journal of Obesity. ,The research team ... oxyntomodulin to fifteen overweight volunteers from Hammersmith Hospital. They ...
... UK couples go abroad in order to undergo fertility treatment. ... own country is that there is a long waiting list ... //were removed by a law. Hence European fertility clinics are ... and Embryology Authority (HFEA) is warning people about the mad ...
... IVF on the grounds that she was a lesbian, ... ,According to Lambda Legal lawyer Jennifer Pizer ... violates California civil rights law. The suit was announced ... doctors however claimed that being fundamental Christians prevented them ...
Cached Medicine News:Health News:Milking the ship of the desert for 'white gold' 2Health News:Watch Out! Sideswipe Elbow Injuries On The Rise 2Health News:Lesbian Sues Doctors 2
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
(Date:8/31/2015)... PARK, Calif. , Aug. 31, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative ... successfully dosed at Chicago -based ... clinical trial evaluating activity of escalating doses of ... with sensory and motor complete cervical spinal cord ...
(Date:8/31/2015)...  QT Vascular Ltd., together with its subsidiaries ... its subsidiaries, the "Group"), a global company engaged ... therapeutic solutions for the minimally invasive treatment of ... the below-the-knee ("BTK") cohort of patients in the ... on August 15, 2015 at the 5th Annual ...
Breaking Medicine Technology:Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... May 3, 2012  Abbott (NYSE: ABT ), ... plans to establish its first nutrition research and development ... leading contract research organization. The Abbott Nutrition R&D Center ... affordable nutrition products for the country and enable the ...
... 2012  Hill-Rom Holdings, Inc. (NYSE: HRC ) announced ... year 2012 third quarter dividend of $0.125 per share. This ... record as of the close of business on June 15, ... Hill-Rom is a leading worldwide manufacturer and provider of ...
Cached Medicine Technology:Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India 2Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India 3Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India 4
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: